Japan Chemical Research, Kissei Submit First Biosimilar Application In Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japan Chemical Research Pharmaceutical of Kobe in Western Japan and Kissei Pharmaceutical of Matsumoto City in central Japan have applied to the Ministry of Health, Labor and Welfare for marketing what is expected to be Japan's first biosimilar therapeutic, spokespersons for the two companies told PharmAsia News Nov. 26
You may also be interested in...
One Year After Japan Paves Way, Follow-on Biologics Start Blossoming
Japan's Ministry of Health, Labor and Welfare has seen an influx of companies interested in bringing products to Japan since releasing official guidelines for biosimilars last March
One Year After Japan Paves Way, Follow-on Biologics Start Blossoming
Japan's Ministry of Health, Labor and Welfare has seen an influx of companies interested in bringing products to Japan since releasing official guidelines for biosimilars last March
MHLW Approves Sandoz's Somatropin As First Biosimilar Product In Japan
TOKYO - Japan's Ministry of Health, Labor and Welfare has approved Sandoz's recombinant human growth hormone somatropin injection, marking it the first biosimilar product approved in Japan, a MHLW Pharmaceutical Examination Division official confirmed June 26